- Home
- ATIF vs CERO Comparison
ATIF vs CERO Comparison
Compare ATIF & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATIF
- CERO
- Stock Information
- Founded
- ATIF 2015
- CERO 2017
- Country
- ATIF United States
- CERO United States
- Employees
- ATIF N/A
- CERO N/A
- Industry
- ATIF Professional Services
- CERO
- Sector
- ATIF Consumer Discretionary
- CERO
- Exchange
- ATIF Nasdaq
- CERO Nasdaq
- Market Cap
- ATIF 8.9M
- CERO 8.5M
- IPO Year
- ATIF 2019
- CERO N/A
- Fundamental
- Price
- ATIF $0.64
- CERO $0.06
- Analyst Decision
- ATIF
- CERO
- Analyst Count
- ATIF 0
- CERO 0
- Target Price
- ATIF N/A
- CERO N/A
- AVG Volume (30 Days)
- ATIF 364.5K
- CERO 22.2M
- Earning Date
- ATIF 12-31-2024
- CERO 11-19-2024
- Dividend Yield
- ATIF N/A
- CERO N/A
- EPS Growth
- ATIF N/A
- CERO N/A
- EPS
- ATIF N/A
- CERO N/A
- Revenue
- ATIF $620,000.00
- CERO N/A
- Revenue This Year
- ATIF N/A
- CERO N/A
- Revenue Next Year
- ATIF N/A
- CERO N/A
- P/E Ratio
- ATIF N/A
- CERO N/A
- Revenue Growth
- ATIF N/A
- CERO N/A
- 52 Week Low
- ATIF $0.58
- CERO $0.05
- 52 Week High
- ATIF $1.50
- CERO $12.80
- Technical
- Relative Strength Index (RSI)
- ATIF 43.99
- CERO 39.14
- Support Level
- ATIF $0.70
- CERO $0.05
- Resistance Level
- ATIF $1.25
- CERO $0.21
- Average True Range (ATR)
- ATIF 0.10
- CERO 0.02
- MACD
- ATIF 0.01
- CERO -0.01
- Stochastic Oscillator
- ATIF 6.39
- CERO 14.60
About ATIF ATIF Holdings Limited
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.